Cytodyn Inc (CYDY)

[DonDonDonDon]

Below is a recent quote from Janet Woodcock where she basically says testing monoclonal antibodies on Mild-to-Moderate was a complete waste of time. She actually uses the word "dumb".

And then she says that they didn't realize it at first but a study of 400 is way too small. It is almost like they was specifically talking about both leronlimab trials.

https://www.ama-assn.org/delivering-care/public-health/fda-experts-discuss-covid-19-therapeutic-clinical-trials

I think at the beginning of this pandemic, we didn't know enough about the disease and its heterogeneity.

For example, monoclonal antibodies, which I was very involved in getting them developed and studied, we took all-comer outpatients and we should have realized that most of the people get better no matter what you do. Treating them with a monoclonal antibody was a dumb idea because it's very hard to treat people. It's expensive and yet they were going to get better on their own and make their own antibodies and they do just fine.

We did very large trials, and yet we only had a very small event rate of hospitalization, and so more trials had to get done and those didn't get into the clinical guidelines and everything until later because of those definitive trials. I think many of the smaller trials were because people naively assumed this was kind of a monotonic disease and we could study like 400 people and that would be really a lot of people to study. That was completely wrong.